Loading stock…

Pfizer Inc. (PFE) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Pfizer Inc.

PFEMarket cap $157BPrice $27.5

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Develops and manufactures prescription drugs and vaccines for diseases affecting millions worldwide. Their COVID-19 vaccine generated over $100 billion in revenue, making it one of the most profitable pharmaceutical products in history.

In Bastion Portfolios?

52W Return+18%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-15%1

Revenue Forecast

Rev CAGR (1y)-0%2

Rev CAGR (3y)-4%1

Rev CAGR (5y)-3%1

Earnings Forecast

EPS Growth Y+1+118%10

EPS Growth Y+2-3%3

EPS Growth Y+3-16%2

Quality

Margins

EBIT Margin30%9

Net Income Margin7%4

Free Cash Flow Margin17%7

Debt

Net Debt/EBITDA2.04

Efficiency

ROE5%3

ROA2%4

Earnings Stability55

GEAR+AVERAGE46

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)109

P/E Ratio (Forward 3y)117

P/BV1.87

EV Multiples

EV/EBITDA Fwd97

EV/EBIT Fwd108

Yield

Free Cash Flow Yield7.0%8

Dividend Yield6.3%10

Momentum

Short term

1 month return-3%6

3 month return+16%9

YTD return+16%7

Mid term

Price vs 52wHigh94%9

1 year return+12%6

Long term

3 year return+1%3

5 year return-16%3

Risk Shield

Price Risk

Beta0.58

Volatility21%9

Free Cash Flow

Free Cash Flow Margin17%7

Free Cash Flow Yield7.0%8

Quality

ROCE11%6

Earnings Stability55

Net Debt/EBITDA2.04

02Growth

Is it actually growing, and how fast?

PFEPfizer

Revenue FY25$62.6B

GROWTH RATING↗

VERY WEAK3 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-15%1

Revenue, next 1Y-0%2

Revenue, next 3Y, CAGR-4%1

Revenue, next 5Y, CAGR-3%1

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+118%10

EPS growth, FY27E-3%3

EPS growth, FY28E-16%2

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue fell 15%/yr over the last 3 years, and it is still set to shrink 4%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 97% of companies worldwide.

Revenue fell 15%/yr over the last 3 years, behind 90% of companies worldwide.1/10

Revenue is set to shrink 4%/yr over the next 3 years, behind most of the market.1/10

Over five years revenue is set to shrink 3%/yr, behind 90% of companies worldwide.1/10

Earnings are set to fall along with revenue (EPS about -3%/yr vs revenue -4%/yr).

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business whose decline is easing. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE62 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return+16%9

YTD return+16%7

MID & LONG-TERM▾SCORE

% of 52-week high94%9

1-year return+12%6

3-year return+1%3

5-year return-16%3

MOMENTUM ASSESSMENT

STRENGTHS

It's up 12% over the past year, now 6% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+16%) and so far this year (+16%).

WATCH

Returns sit at the market level over the past month (-3%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+0.7% over three years and -16% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Pfizer. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

PFEPfizer

Revenue FY25$62.6B

GROWTH RATING↗

VERY WEAK3 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-15%1

Revenue, next 1Y-0%2

Revenue, next 3Y, CAGR-4%1

Revenue, next 5Y, CAGR-3%1

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+118%10

EPS growth, FY27E-3%3

EPS growth, FY28E-16%2

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue fell 15%/yr over the last 3 years, and it is still set to shrink 4%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 97% of companies worldwide.

Revenue fell 15%/yr over the last 3 years, behind 90% of companies worldwide.1/10

Revenue is set to shrink 4%/yr over the next 3 years, behind most of the market.1/10

Over five years revenue is set to shrink 3%/yr, behind 90% of companies worldwide.1/10

Earnings are set to fall along with revenue (EPS about -3%/yr vs revenue -4%/yr).

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business whose decline is easing. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE62 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return+16%9

YTD return+16%7

MID & LONG-TERM▾SCORE

% of 52-week high94%9

1-year return+12%6

3-year return+1%3

5-year return-16%3

MOMENTUM ASSESSMENT

STRENGTHS

It's up 12% over the past year, now 6% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+16%) and so far this year (+16%).

WATCH

Returns sit at the market level over the past month (-3%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+0.7% over three years and -16% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Pfizer. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community